Cancer/testis antigen MAGE-A4 expression pattern differs in epithelial skin tumors of organ-transplant recipients and immunocompetent patients

Journal of Cutaneous Pathology

Volumn 34, Issue 1, 2007, Pages 1-6

  Muehleisen, Beda ^a   Schaerer, Leo ^a   Dummer, Reinhard ^a   Burg, Günter ^a   Hofbauer, Günther F L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; MELANOMA ANTIGEN 4; MONOCLONAL ANTIBODY; PARAFFIN;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BOWEN DISEASE; BOWENOID PAPULOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN CARCINOGENESIS; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STAINING;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BOWEN'S DISEASE; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; KERATOSIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGAN TRANSPLANTATION; SKIN NEOPLASMS; TISSUE DISTRIBUTION;

EID: 33846067640     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00576.x     Document Type: Article

References (40)

1. Berg D, Otley CC. Skin cancer in organ transplant recipients. Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1.
2. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681.
3. Cebon J, MacGregor D, Scott A, DeBoer R. Immunotherapy of melanoma: targeting defined antigens. Australas J Dermatol 1997; 38 (Suppl. 1): S66.
4. Chi DD, Merchant RE, Rand R et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150: 2143.
5. Gillespie AM, Coleman RE. The potential of melanoma antigen expression in cancer therapy. Cancer Treat Rev 1999; 25: 219.
6. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182: 323.
7. Coulie PG, Karanikas V, Lurquin C et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33.
8. Bettinotti MP, Panelli MC, Ruppe E et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12: 170-178. Int J Cancer 2003; 105: 210.
9. Marchand M, Punt CJ, Aamdal S et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 70.
10. Usener D, Gerhardt A, Schadendorf D, Eichmuller S. Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. Br J Dermatol 2003; 149: 282.
11. Hersey P, Menzies SW, Halliday GM et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004; 53: 125.
12. Nagao T, Higashitsuji H, Nonoguchi K et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 2003; 278: 106684.
13. Xiao J, Chen HS. Biological functions of melanoma-associated antigens. World J Gastroenterol 2004; 10: 1849.
14. Li J, Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 2002; 41: 3977.
15. Brasseur F, Rimoldi D, Lienard D et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375.
16. Hofbauer GF, Schaefer C, Noppen C et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151: 1549.
17. Hofbauer GF, Dummer R, Laine E, Burg G. Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA. Arch Dermatol Res 1998; 290: 458.
18. Basarab T, Picard JK, Simpson E, Russell-Jones R. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. Br J Dermatol 1999; 140: 106.
19. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000; 13: 459.
20. Hofbauer GF, Geertsen R, Laine E, Burg G, Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res 2001; 11: 213.
21. Kazakov DV, Kutzner H, Rutten A et al. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions. Am J Dermatopathol 2004; 26: 102.
22. Lüftl M, Schuler G, Jungbluth AA. Melanoma or not? Cancer testis antigens may help. Br J Dermatol 2004; 151: 1213.
23. Prasad ML, Jungbluth AA, Patel SG, Iversen K, Hoshaw-Woodard S, Busam KJ. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 2004; 26: 1053.
24. Chambost H, Van Baren N, Brasseur F et al. Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 2000; 95: 3530.
25. Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 2002; 101: 190.
26. Dhodapkar MV, Osman K, Teruya-Feldstein J et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immunity 2003; 3: 9.
27. Rajpert-De Meyts E, Jacobsen GK, Bartkova J et al. The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE-A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminoma. Histopathology 2003; 42: 217.
28. Sarcevic B, Spagnoli GC, Terracciano L et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 2003; 64: 443.
29. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003; 9: 6453.
30. Bolli M, Kocher T, Adamina M et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002; 236: 785.
31. Bolli M, Schultz-Thater E, Zajac P et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 2005; 115: 960.
32. Landry C, Brasseur F, Spagnoli GC et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86: 835.
33. Jones R, Freeman R, Mascaro J, Kerl H. Questions to the editorial board and other authorities. Am J Dermatopathol 1984; 6: 301.
34. Kirkham N. Tumors and cysts of the epidermis. In Elder D, eds. Lever's histopathology of the skin. Philadelphia: Lippincott-Raven, 1997; 685.
35. Ackerman A. A philosophy of practice in of surgical pathology: dermatopathology as model. Philadelphia, PA: Ardor Scribendi, 1999; 96.
36. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol 1999; 41: 443.
37. Kocher T, Schultz-Thater E, Gudat F et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995; 55: 2236.
38. Cordell J, Falini B, Erber WN, Ghosh AK, Abdulaziz Z. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-229.
39. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446.
40. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571: 185.